Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Bull Horn Holdings (BHSEU)
New Beginnings Acquisition (NBA.U)
CONX (CONXU)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Cerberus Telecom Acquisition (CTACU)
Upcoming IPO
OTR Acquisition (OTRAU)
Natural Order Acquisition (NOACU)
Priced IPO
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
More companies

COMPASS Pathways plc (CMPS)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. They are motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Their initial focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the current treatment paradigm. They have developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360. In 2019, they completed a Phase I clinical trial administering COMP360, along with psychological support, to 89 healthy volunteers, the largest randomized controlled clinical trial with psilocybin therapy to date. In this trial they observed that COMP360 was generally well-tolerated. They are currently evaluating COMP360 in conjunction with psychological support in a Phase IIb trial and they plan to report data from this trial in late 2021. They believe that a single dose of their COMP360 monotherapy with psychological support from specially trained therapists could offer a new approach to depression care.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
-
Employees Founded
48 2015

Contacts

Address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom

Telephone: +1 (646) 905-3974.

Web page: http://www.compasspathways.com

IPO information

Expected Date 9/18/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $591.6
Revenues (MM) $0
Net Income (Loss) (MM) $-38.8

Voting

What do you think will happen with the CMPS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 6.7
Shares Revised (MM) 7.5
Expected offer amount (MM) $100
Realized offer amount(MM) $127.5
Underwriters
Cowen/ Evercore ISI/ Berenberg
CO-Managers
Canaccord Genuity

Sector: Healthcare

Tweets about $CMPS

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats